PainReform announced encouraging early safety results from its ongoing Phase 3 bunionectomy study of PRF-110, the Company’s proprietary post-surgical pain formulation. The study, which has now completed full enrollment with a total of 443 patients across eight clinical sites in the United States, is designed as a randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of PRF-110 in patients undergoing bunionectomy, a common outpatient surgical procedure. Initial safety data from the study revealed a low incidence of adverse events, averaging just one per subject.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRFX:
- PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study
- PainReform Reports Significant Asset Decline
- PainReform Provides Business Update for the Second Quarter of 2024
- PainReform reports 1H net loss $12.8M vs. $4.5M last year
- PainReform Shareholders Approve Key Proposals